# Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

> **NCT00450970** · PHASE3 · TERMINATED · sponsor: **Agennix** · enrollment: 344 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Oral Satraplatin

## Key facts

- **NCT ID:** NCT00450970
- **Lead sponsor:** Agennix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02
- **Primary completion:** 2009-03
- **Final completion:** 2009-12
- **Target enrollment:** 344 (ACTUAL)
- **Why stopped:** Sponsor decided to discontinue study drug development.
- **Last updated:** 2012-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450970, "Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00450970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*